Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: A Phase II study of the Cancer and Leukemia Group B (CALGB 9041)

Investigational New Drugs

Volumn 22, Issue 1, 2004, Pages 83-89

  Kimmick, Gretchen ^a   Ratain, Mark J ^b   Berry, Don ^c   Woolf, Susan ^d   Norton, Larry ^e   Muss, Hyman B ^f  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d CALGB Statistical Center   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF VERMONT   (United States)

Author keywords

Breast cancer; Interferon (IFN) alpha 2a; Metastatic; Recombinant human interleukin 2 (rIL 2)

Indexed keywords

ALPHA2A INTERFERON; HORMONE RECEPTOR; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DYSPNEA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERHIDROSIS; HYPOTENSION; INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; MALAISE; METASTASIS; MOOD DISORDER; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RASH; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; INTERLEUKIN-2; MIDDLE AGED; NEOPLASM METASTASIS; RECOMBINANT PROTEINS; SURVIVAL RATE;

EID: 1042279666     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DRUG.0000006178.32718.22     Document Type: Article

References (30)

1. Anonymous: Polychemotherapy for early breast cancer: An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352: 930-942, 1998
2. Anonymous: Tamoxifen for early breast cancer: An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351: 1451-1467, 1998
3. Ellis MJ, Hayes DF, Lippman ME: Treatment of metastatic breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the Breast, Ch. 48. Philadelphia, 2000, pp 749-797
4. Rosenberg SA, Schwarz SL, Spiess RJ: Combination immunotherapy for cancer: Synergistic antitumor interactions of interleukin-2, alpha interferon, and tumor-infiltrating lymphocytes. J Natl Cancer Inst 80: 1393-1397, 1988
5. Mittelman A, Huberman M, Puccio C, Fallon B, Tessitore J, Savona S, Eyre R, Gafney E, Wick M, Skelos A: A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma. Cancer 66: 664-669, 1990
6. Lee KH, Talpaz M, Rothberg JM, Murray JL, Papadopoulos N, Plager C, Benjamin R, Levitt D, Gutterman J: Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: A phase I study. J Clin Oncol 7: 1726-1732, 1989
7. Ratain MJ, Priest ER, Janisch L, Vogelzang NJ: A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a. Cancer 71: 2371-2376, 1993
8. Dunton AW, Cohen FC, Lipman A et al.: Clinical and immunologic effects of recombinant IL-2 given subcutaneously to patients with solid tumors. Clin Res 37: 465A, 1989
9. Robertson JF, Howell A, Buzdar A, von Euler M, Lee D: Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. Breast Cancer Res Treat 58: 157-162, 1999
10. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
11. Cox DR: Regression models and life tables (with discussion). J Royal Stat Soc 34: 187-220, 1972
12. Hadden JW: The immunology and immunotherapy of breast cancer: An update. Int J of Immunopharmacol 21: 79-101, 1999
13. Allison MAK, Jones SE, McGuffey P: Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors. J Clin Oncol 7: 75-80, 1989
14. Walters RS, Theriault RL, Holmes FA, Esparza L, Hortobagyi GN: Phase II study of recombinant alpha-interferon and recombinant interleukin-2 metastatic breast cancer. J Immunother Emphaiss Tumor Immunol 16: 303-305, 1994
15. Budd GT, Osgood B, Bama B, Boyett JM, Finke J, Medendom SV, Murphy S, Novak C, Sergi J, Tubbs R, Bukowski RM: Phase I clinical trail of interleukin-2 and alpha-interferon: Toxicity and immunologic effects. Cancer Res 49: 6432-6436, 1989
16. Paciotti GF, Tamarkin L: Interleukin-2 differentially affects the proliferation of a hormone-dependent and a hormone-independent human breast cancer cell line in vitro and in vivo. Anticancer Res 8: 1233-1240, 1988
17. Nicolini A, Mancini PA, Ferarri P, Anselmi L, Sagripanti A, Carpi A: Immunological and side effects of low sc recombinant interleukin-2 dose in addition to conventional treatment in relapsed breast and colorectal cancer patients. Biomed Pharmacother 50: 344-349, 1996
18. Vandenberg HW, Leahey WJ, Lynch M, Clarke R, Nelson J: Recombinant human interferon-alpha increases estrogen-receptor expression in human-breast cancer-cells (Zr-75-1) and sensitizes them to the antiproliferative effects of tamoxifen. Br J Cancer 55: 255-257, 1987
19. Sica G, Natoli V, Stella C, Delbianco S: Effect of natural interferon-beta on cell-proliferation and steroid-receptor level in human-breast cancer-cells. Cancer 60: 2419-2423, 1987
20. Pouillart P, Palangie T, Jouve M, Garcia-Giralt E, Fridman WH, Magdelenat H, Falcoff E, Billau A: Administration of fibroblast interferon to patients with advanced breast cancer: Possible effects on skin metastases and on hormone receptors. Eur J Cancer Clin Oncol 18: 929-935, 1982
21. Iacopino F, Della Cuna GR, Sica G: Natural interferon-alpha activity in hormone-sensitive, hormone-resistant and autonomous human breast-cancer cell lines. Int J Cancer 71: 1103-1108, 1997
22. Bezwoda WR, Meyer K: Effect of alpha-interferon, 17 beta-estradiol, and tamoxifen on estrogen receptor concentration and cell cycle kinetics of MCF 7 cells. Cancer Res 50: 5387-5391, 1990
23. Seymour L, Bezwoda WR: Interferon plus tamoxifen treatment for advanced breast cancer: In vivo biologic effects of two growth modulators. Br J Cancer 68: 352-356, 1993
24. Kornek G, Reiner A, Sagaster P, Stierer M, Mayer A, Ludwig H: Effect of interferon alpha-2a on hormone receptor status in patients with advanced breast cancer. Cancer Invest 17: 189-194, 1999
25. Macheledt JE, Buzdar AU, Hortobagyi GN, Frye DK, Gutterman JU, Holmes FA: Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer. Breast Cancer Res Treat 18: 165-170, 1991
26. Miglietta L, Repetto L, Gardin G, Amoroso D, Giudici S, Naso C, Merlini L, Queirolo P, Campora E, Pronzato, P et al.: Tamoxifen and alpha interferon in advanced breast cancer. J Chemother 3: 383-386, 1991
27. Repetto L, Giannessi PG, Campora E, Pronzato P, Vigani A, Naso C, Spinelli I, Conte PF, Rosso R: Tamoxifen and interferon-beta for the treatment of metastatic breast cancer. Breast Cancer Res Treat 39: 235-238, 1996
28. Skeel R. T, Quan, WDY, Palackdharry CS: Common Cancers - immunotherapy and multidisciplinary therapy: Part III and IV. In: Greenberger N.J, Kohler P. O, Levin S, Lipschitz DA (43), 747-781. 1997. St. Louis, MO, Mosby - Year Book, Inc. Disease-a-Month
29. Atkins MB, Sparano J, Fisher RI, Weiss GR, Margolin KA, Rink KI, Rubinstein L, Loui A, Mier JW, Gucalp R: Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alpha-2b in advanced renal cell carcinoma. J Clin Oncol 11: 611-670, 1993
30. Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Micetich KC, Weiss GR: Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 11: 1969-1977, 1993